A Phase I/II study of Lu-177-DOTAGA-IAC in angiogenic breast cancer

Not Yet Recruiting Phase 1,Phase 2 NCT04469127

Study Description

A study evaluating a new investigational drug, Lu-177-DOTAGA-IAC (HurlutinTM Lu-177), for the treatment of advanced breast cancer

Study Details

Registry ID:: NCT04469127
Conditions:: Breast Cancer Stage IV
Phase:: Phase 1,Phase 2
Target Enrollment:: 100 participants
Start Date:: September 30, 2024
Age Range:: 18–80 years
Healthy Volunteers:: No

Study Locations (4 sites)

CM Johannesburg Academic Hospital, University of the Witwatersrand
JohannesburgSouth Africa, South Africa
All India Institute of Medical Sciences
New Delhi, DehliIndia, India
Postgraduate Institute of Medical and Research
ChandigarhIndia, India
Department of Veterans Affairs
Iowa City, IowaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →